Vasoactive Peptides in Portal Pressure

The recruitment status of this study is unknown because the information has not been verified recently.

Verified September 2005 by Bayside Health. Recruitment status was Recruiting

First Received on September 13, 2005. Last Updated on July 25, 2007 History of Changes

Sponsor:	Bayside Health
Information provided by:	Bayside Health
ClinicalTrials.gov Identifier:	NCT00163982

Purpose

This study is looking at the detection of vasoactive peptides in portal hypertension.

Condition	Intervention
Portal Hypertension	Drug: Norfloxacin

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Crossover Assignment Masking: Double-Blind Primary Purpose: Treatment

Resource links provided by NLM:

MedlinePlus related topics: High Blood Pressure

Drug Information available for: Norfloxacin

U.S. FDA Resources

Further study details as provided by Bayside Health:

Eligibility

Ages Eligible for Study:	18 Years to 75 Years
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:

HVPG >= 12 mmHg

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00163982

Contacts

Contact: William W Kemp, MBBS, FRACP

92762000 ext 3327

w.kemp@alfred.org.au

Locations

Australia, Victoria
Alfred Hospital	Recruiting
Melbourne, Victoria, Australia, 3181
Contact: William W Kemp, MBBS, FRACP 92762000 ext 3327 w.kemp@alfred.org.au

Sponsors and Collaborators

Bayside Health

Investigators

Principal Investigator:

William W Kemp, MBBS, FRACP

The Alfred

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00163982 History of Changes
Other Study ID Numbers:	AH4204
Study First Received:	September 13, 2005
Last Updated:	July 25, 2007
Health Authority:	Australia: Human Research Ethics Committee

Keywords provided by Bayside Health:

HVPG > 12 mmHg

Additional relevant MeSH terms:

Hypertension
Hypertension, Portal
Vascular Diseases
Cardiovascular Diseases
Liver Diseases
Digestive System Diseases
Norfloxacin

Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Nucleic Acid Synthesis Inhibitors
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 21, 2012